Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study

Hasan Chichan,1,2 Matthias Maus,2,* Ludwig M Heindl1,3,* 1Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, 50923, Germany; 2Sehkraft Eye Center, Cologne, 50667, Germany; 3Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duessel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chichan H, Maus M, Heindl LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	sub threshold nanosecond laser therapy age-related macular degeneration ophthalmology drusen ocular surgery Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e8418d8e974e47babc05d2decb3abff8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e8418d8e974e47babc05d2decb3abff8
record_format	dspace
spelling	oai:doaj.org-article:e8418d8e974e47babc05d2decb3abff82021-12-02T14:47:30ZSubthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study1177-5483https://doaj.org/article/e8418d8e974e47babc05d2decb3abff82021-05-01T00:00:00Zhttps://www.dovepress.com/subthreshold-nanosecond-laser-from-trials-to-real-life-clinical-practi-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Hasan Chichan,1,2 Matthias Maus,2,* Ludwig M Heindl1,3,* 1Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, 50923, Germany; 2Sehkraft Eye Center, Cologne, 50667, Germany; 3Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Cologne, 50937, Germany*These authors contributed equally to this workCorrespondence: Hasan Chichan Email chichan@sehkraft.deBackground: Age-related macular degeneration (AMD), a degenerative disorder, is a major cause of irreversible severe visual deterioration in the older Western population. Thus, treatments that resolve drusen may prove helpful in limiting the progression of AMD. The study aimed to evaluate the clinical outcome of sub-threshold nanosecond laser therapy (SNL) using a double-frequency nanosecond-pulsed laser with discontinuous energy beam distribution in the early stages of age-related macular degeneration (AMD).Methods: In a single-center cohort study, 64 eyes with early or intermediate AMD were treated using SNL and then compared to 77 untreated, control eyes. The primary outcome measures included the area and amount of drusen, and the secondary outcome measures included change in visual acuity and rate of drusen progression within 6 months of follow-up.Results: A total of 64 patients’ eyes following SNL treatment showed a significant reduction in the area and amount of drusen after 6 months in comparison to the corresponding values in the control group (p< 0.001, respectively). There was no significant difference in visual acuity change after 6 months in both groups (p 0.59, respectively). Within the 6-month follow-up, the rate of progression in drusen size and number was significantly lower in the SNL group (26%) than in the control group (69%; p< 0.001).Discussion: SNL therapy is a novel, promising approach for improving the macular morphology in patients with early and intermediate AMD. Further studies are necessary to reveal the potential to reduce the risk of transformation into advanced or wet AMD and to retain vision.Keywords: subthreshold nanosecond laser therapy, age-related macular degeneration, ophthalmology, drusen, ocular surgeryChichan HMaus MHeindl LMDove Medical Pressarticlesub threshold nanosecond laser therapyage-related macular degenerationophthalmologydrusenocular surgeryOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1887-1895 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sub threshold nanosecond laser therapy age-related macular degeneration ophthalmology drusen ocular surgery Ophthalmology RE1-994
spellingShingle	sub threshold nanosecond laser therapy age-related macular degeneration ophthalmology drusen ocular surgery Ophthalmology RE1-994 Chichan H Maus M Heindl LM Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study
description	Hasan Chichan,1,2 Matthias Maus,2,* Ludwig M Heindl1,3,* 1Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, 50923, Germany; 2Sehkraft Eye Center, Cologne, 50667, Germany; 3Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Cologne, 50937, Germany*These authors contributed equally to this workCorrespondence: Hasan Chichan Email chichan@sehkraft.deBackground: Age-related macular degeneration (AMD), a degenerative disorder, is a major cause of irreversible severe visual deterioration in the older Western population. Thus, treatments that resolve drusen may prove helpful in limiting the progression of AMD. The study aimed to evaluate the clinical outcome of sub-threshold nanosecond laser therapy (SNL) using a double-frequency nanosecond-pulsed laser with discontinuous energy beam distribution in the early stages of age-related macular degeneration (AMD).Methods: In a single-center cohort study, 64 eyes with early or intermediate AMD were treated using SNL and then compared to 77 untreated, control eyes. The primary outcome measures included the area and amount of drusen, and the secondary outcome measures included change in visual acuity and rate of drusen progression within 6 months of follow-up.Results: A total of 64 patients’ eyes following SNL treatment showed a significant reduction in the area and amount of drusen after 6 months in comparison to the corresponding values in the control group (p< 0.001, respectively). There was no significant difference in visual acuity change after 6 months in both groups (p 0.59, respectively). Within the 6-month follow-up, the rate of progression in drusen size and number was significantly lower in the SNL group (26%) than in the control group (69%; p< 0.001).Discussion: SNL therapy is a novel, promising approach for improving the macular morphology in patients with early and intermediate AMD. Further studies are necessary to reveal the potential to reduce the risk of transformation into advanced or wet AMD and to retain vision.Keywords: subthreshold nanosecond laser therapy, age-related macular degeneration, ophthalmology, drusen, ocular surgery
format	article
author	Chichan H Maus M Heindl LM
author_facet	Chichan H Maus M Heindl LM
author_sort	Chichan H
title	Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study
title_short	Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study
title_full	Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study
title_fullStr	Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study
title_full_unstemmed	Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study
title_sort	subthreshold nanosecond laser, from trials to real-life clinical practice: a cohort study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/e8418d8e974e47babc05d2decb3abff8
work_keys_str_mv	AT chichanh subthresholdnanosecondlaserfromtrialstoreallifeclinicalpracticeacohortstudy AT mausm subthresholdnanosecondlaserfromtrialstoreallifeclinicalpracticeacohortstudy AT heindllm subthresholdnanosecondlaserfromtrialstoreallifeclinicalpracticeacohortstudy
_version_	1718389540834508800

Subthreshold Nanosecond Laser, from Trials to Real-Life Clinical Practice: A Cohort Study

Ejemplares similares